CLEWICU System is an AI-enabled medical device from Clew Medical Ltd. that the U.S. FDA cleared through 510(k) K233216 on January 13, 2024. Its lead review panel is Cardiovascular and its primary product code is QNL (Medium-Term Adjunctive Predictive Cardiovascular Indicator).
See also FDA-cleared AI cardiovascular devices in 2024, all FDA AI clearances in 2024, top cardiovascular AI devices.
Key facts
| Submission number | K233216 |
|---|---|
| Pathway | 510(k) |
| Date of final decision | |
| Company (FDA list) | Clew Medical Ltd. |
| Lead review panel | Cardiovascular |
| Primary product code | QNL — Medium-Term Adjunctive Predictive Cardiovascular Indicator |
| Applicant (openFDA) | Clew Medical , Ltd. |
| Applicant location | Poleg, IL |
| Device class | Class 2 |
| Regulation number | 21 CFR 870.2210 |
| Decision code | SESE |
| Submission type | Traditional |
Source: FDA AI-Enabled Medical Devices list and openFDA.
What this means
A 510(k) is a premarket submission showing the device is substantially equivalent to a legally marketed predicate device. A cleared 510(k) means FDA agreed with that equivalence. CLEWICU System went through this pathway (K233216).
openFDA lists it as a Class 2 device under 21 CFR 870.2210. Class II devices are moderate risk and are subject to general and special controls.
Product code QNL covers 5 devices on the FDA AI list. By decision date, this device is #4 of 5 under that code. Clew Medical Ltd. has 2 AI-enabled devices on the list, and the Cardiovascular panel accounts for 154 in total.
Being on this list doesn't describe how well the device works clinically. Check the FDA record for its indications for use.
Similar devices (product code QNL)
- eCARTv5 Clinical Deterioration Suite (eCART)AgileMD, Inc. · Cardiovascular
- SignalHF (IM008)Implicity Inc. · Cardiovascular
- Global Hypoperfusion Index (GHI) AlgorithmEdwards Lifesciences, LLC · Cardiovascular
- CLEWICU System (ClewICUServer and ClewICUnitor)CLEW Medical Ltd. · Cardiovascular